News Archives

Global push for medical vest that aims to enable cancer treatment for children

11

Sep

For seriously ill children and adolescents, intravenous drip stands can significantly hinder mobility. Umeå based Nil Medical has developed an ergonomic medical vest that conceals fluids, pumps, and tubing within the garment, allowing for unrestricted play and movement.
A national quality-of-life study is underway, in collaboration with Swedish healthcare, and Nil Medical aims to introduce the vest to the international market.

AlexoTech achieves record turnover and sees significant growth potential

06

Sep

Swedish biotech company AlexoTech set a new turnover record in 2023 and predicts another strong performance this year. Citing Agrisera as a local role model, CEO and founder Anders Olofsson believes there are plenty of opportunities for Umeå based AlexoTech to expand.

QureTech Bio appoints new CEO: “Strive to bring our substances to clinical trials”

03

Sep

Umeå based QureTech Bio, a biotechnology company developing novel antibiotics and anti-infectives, has appointed Markus Thor as the new Chief Executive Officer.
“Along with the team, I will strive to bring our substances to clinical trials”, he states.

Interview: Boreal Orchards contributes to solutions for new EU legislation

20

Aug

On June 17th, Boreal Orchards delivered their first batch of moss primer to Kiruna as part of the re:moss project. That same day, the EU Council adopted the Nature Restoration Law, the first comprehensive, continent-wide legislation of its kind. The law sets binding targets and obligations for EU member states to rehabilitate at least 20 percent of the EU’s land and sea areas by 2030 and all degraded ecosystems by 2050.

QureTech Bio appoints new Chairman of the Board and new Board Member

12

Aug

QureTech Bio AB, a biotech company that develops novel antibiotics, has announced the appointment of Lennart Hansson as its new Chairman of the Board. Hansson succeeds Sven Bergström, who is stepping down after a successful tenure leading the company’s strategic direction.

New UBI Case Aims to Revolutionize Treatment of Cryptosporidiosis

17

Jun

Cryptosporidiosis is one of the biggest threats to newborn calves in the global agricultural industry. It is also responsible for hundreds of thousands of human deaths in developing countries each year.
There is currently no effective treatment for the disease, but a new case at UBI is set to change that. Professor Christian Hedberg is developing a new drug with the potential to revolutionize the treatment of cryptosporidiosis worldwide.

HiloProbe secures 3 SEK Million in funding for sales initiation

11

Jun

Umeå based HiloProbe has raised an additional SEK 3 Million in funding from existing owners. This capital injection is a step towards achieving the next goal.

SEK 22 million in EU funding elevates the Life Science sector in Umeå

03

Jun

Umeå is strengthening its position as a life science hub thanks to two regional development projects receiving around €1.8 million (22 SEK million) in EU support. These projects aim to boost innovation, collaboration, and industry growth.
“This presents an opportunity to further elevate Umeå’s standing as a life science leader,” emphasizes Peter Jacobsson, Operations Coordinator at Umeå Biotech Incubator (UBI).

Founders of Xerum win Umeå University and Nordea’s Utilisation Award.

27

May

Mattias Forsell, Johan Normark and Julia Wigren Byström, the founders of the UBI Alumni Xerum AB, have been awarded Umeå University’s and Nordea’s Innovation Prize for utilisation 2024. This is for the successful COVID-19 research conducted by a clinician, a preclinical researcher, and a biomedical analyst.

MetaCurUm aims to raise SEK 100 Million – following founder’s prestigious Award

23

May

Maréne Landström, a professor of pathology at Umeå University, was named Sweden’s Cancer Researcher of the Year for 2024. Her groundbreaking research is currently being developed into a cancer treatment by the company MetaCurUm Biotech AB, which is gearing up to raise new capital for its next phase.
“MetaCurUm is aiming to secure around 100 million SEK, with substantial interest already shown by institutional investors in Sweden and Europe”, says, CEO Maarten de Château.

Mucocort initiates clinical trial of innovative patch for aphthous stomatitis

07

May

Mucocort AB has received approval from the Swedish Medical Products Agency and the Ethics Review Board to commence a clinical trial of an intraoral patch (M045A) for the treatment of aphthous stomatitis, a condition affecting approximately 2 percent of the population and causing frequent mouth ulcers with significant pain for affected patients.
“We are pleased to soon be ready to welcome our first patient to the trial,” says Jean Lycke, project manager for Mucocort AB.

SpinChem joins trailblazing alliance: “We can make a difference in the world”

06

May

SpinChem joins the Enzyme Technology Alliance – a group of six trailblazing European companies, collaborating to bring competitive solutions for the biotech industry to market at scale.
“In the Alliance, we can tackle complex challenges and offer solutions previously unimaginable”, says Emil Byström, CEO of SpinChem.

APL invests 40 Million SEK in Umeå

30

Apr

APL (Apotek Production & Laboratorier AB) is committing 40 million SEK to establish a new sterile pharmaceutical production line at its Umeå site. This strategic move is both a response to new manufacturing regulations and an enhancement of the plant’s output capabilities, including acquiring new machinery and constructing additional facilities.
“The dynamic environment in Umeå is perfectly suited for our growth,” says Erik Haeffler, CEO of APL, to UBI.

New lab fair attracts 18 companies to Umeå

23

Apr

Lab companies often visit Umeå one at a time. That’s why Umeå Biotech Incubator (UBI) organizes the Umeå Lab Fair on the 25th of April, featuring 18 participating companies.
“By bringing everyone together on the same occasion, we create added value for exhibitors and visitors”, says Christin Grundström, Laboratory and Community Manager at UBI.

SpinChem named University Spin-Off of the Year

22

Mar

SpinChem triumphed at the Umeå Gala on Thursday, clinching the ‘University Spin-Off of the Year’ award.
“It gives the whole team a boost of motivation,” commented CEO Emil Byström.

Diamyd expands the team in Umeå for upscaled production of technical batches

22

Mar

Diamyd Medical actively expands its workforce in Umeå, focusing on recruiting individuals with key competencies.
”The production of the technical batches is ongoing and we are scaling up our workforce accordingly”, says Martin Linhult, CMC Lead.

Here are the skills required by the companies – read the Life Science Umeå Job Fair Magazine

19

Mar

The magazine about the Life Science Umeå Job Fair includes:
* Interviews with all 18 participating companies.
* A Map of Life Science Umeå.
* Guide to how to stay tuned about the industry in Umeå.
* Stories & News from now and then about Life Science Umeå.
* A chronicle by Peter Jacobsson, Operations Coordinator at UBI.

Umeå Municipality aims for 500 Life science jobs with new establishment strategy

19

Mar

Life science has become a priority growth target for Umeå Municipality, strategically encouraging life science companies to establish themselves in the region.
“The goal is for an organization with at least 500 employees to set up operations here. We already have the infrastructure needed to make us attractive to larger companies”, says Peter Juneblad, Business Director at Umeå Municipality.

Financial Times ranks UBI as one of Europe’s Leading Start-Up Hubs

14

Mar

The Financial Times has recognized Umeå Biotech Incubator (UBI) as one of “Europe’s Leading Start-Up Hubs”.
“This is an acknowledgment that our efforts are competitive, even globally,” says Peter Jacobsson, UBI’s operation coordinator.

New UCMR Directors focus on BSL-3 labs and clinical ties

06

Mar

Fredrik Almqvist and Marta Bally have been appointed as the new Directors of UCMR, the hub for microbial infection research at Umeå University. Their forward agenda includes enhancing collaboration with clinical research and establishing Biosafety Level 3 (BSL-3) labs for both in vitro and in vivo experiments.
“To stay at the forefront and recruit the best researchers, it’s crucial to have modern BSL-3 labs,” says Fredrik Almqvist.